Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in JIA subtypes (JUNIPERA)
NCT03031782Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2017
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in juvenile psoriatic arthritis (JPsA) and enthesitis-related juvenile idiopathic arthritis (ERA) comparing Secukinumab with Placebo (2 arms). Primary endpoint: Time to Disease Flare in Treatment Period 2. Started May 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
juvenile psoriatic arthritis (JPsA)enthesitis-related juvenile idiopathic arthritis (ERA)
Beyond the preview
Go deeper on NCT03031782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031782.